Clinical Trial Update: Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the clinical outcomes and cost-effectiveness of ramipril, an ACE inhibitor, in patients with intermittent claudication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Artery Disease

Drugs mentioned

• Ramipril (ramipril)

Snippet

Sponsor: Hull University Teaching Hospitals NHS Trust | Conditions: Intermittent Claudicants | Phase 4 | Status: COMPLETED | Results posted: 2025-12-18